Abstract
BIMG-07. PHARMACOLOGICAL ASCORBATE ENHANCES RADIATION AND TEMOZOLOMIDE EFFECTIVENESS IN GLIOBLASTOMA BY A MECHANISM MEDIATED BY REDOX ACTIVE IRON
Neuro-oncology advances, Vol.3(Suppl 1), pp.i2-i2
03/25/2021
DOI: 10.1093/noajnl/vdab024.006
PMCID: PMC7992261
Abstract
Pharmacological ascorbate (P-AscH
-
; high dose intravenous infusions of vitamin C generating milli-molar plasma concentrations) has re-emerged as an anti-cancer therapy. Phase 1 clinical trials combining P-AscH
-
with chemotherapy and ionizing radiation demonstrate safety and promising clinical outcomes in a variety of malignancies. In a first-in-human trial, subjects with newly diagnosed glioblastoma (GBM) and undetectable
MGMT
promoter methylation were treated with P-AscH
-
, ionizing radiation, and temozolomide. Results demonstrate median progression-free survival (PFS) of 10 months and median overall survival (OS) of 23 months, comparing favorably to historical GBM patients expressing MGMT. P-AscH
-
‘s anti-cancer mechanism is dependent upon the presence of redox active labile iron. In the presence of redox active iron, the formation of hydrogen peroxide, which causes oxidative stress and eventual cell death, selectively forms in cancer cells. Treatment with P-AscH
-
increased cancer cells’ labile iron pool, further enhancing sensitivity to P-AscH
-
. We investigated the capability of MR imaging (T
2
* relaxation time) to measure the redox active iron and predict response to P-AscH
-
. T
2
* relaxation time is influenced by in-field inhomogeneities, such as redox active paramagnetic iron. The active phase 2 trial evaluating P-AscH
-
, radiation, and temozolomide for GBM, obtains T
2
* imaging prior to (baseline) and immediately after ascorbate infusion (NCT02344355). A preliminary analysis of the baseline scan for the first 15 subjects suggests those with faster GBM T
2
* relaxation times (≤ 58 ms) have more redox active labile iron pools as well as an improved median PFS (11.4 months) compared to those with slower T
2
* relaxation times (> 58 ms; median PFS of 8.5 months). Pre-clinical studies evaluating the effectiveness of iron nano-particle supplementation in GBM animal models are on-going. (Supported by P01 CA217797, R01 CA169046, U01 CA140206, T32 CA078586, P30 CA086862, as well as the Gateway for Cancer Research grant G-17–1500.)
Details
- Title: Subtitle
- BIMG-07. PHARMACOLOGICAL ASCORBATE ENHANCES RADIATION AND TEMOZOLOMIDE EFFECTIVENESS IN GLIOBLASTOMA BY A MECHANISM MEDIATED BY REDOX ACTIVE IRON
- Creators
- Bryan Allen - University of IowaMichael Petronek - University of IowaVarun Monga - University of IowaKellie Bodeker - University of IowaBrian Smith - University of IowaGarry Buettner - University of IowaJeremy Greenlee - , , , ,Mark Smith - University of IowaDouglas Spitz - University of IowaJoseph Cullen - University of IowaVincent Magnotta - University of IowaJohn Buatti - University of Iowa
- Resource Type
- Abstract
- Publication Details
- Neuro-oncology advances, Vol.3(Suppl 1), pp.i2-i2
- DOI
- 10.1093/noajnl/vdab024.006
- PMCID
- PMC7992261
- ISSN
- 2632-2498
- eISSN
- 2632-2498
- Publisher
- Oxford University Press
- Language
- English
- Date published
- 03/25/2021
- Academic Unit
- Psychiatry; Pathology; Biostatistics; Surgery; Otolaryngology; Roy J. Carver Department of Biomedical Engineering; Radiology; Hematology, Oncology, and Blood & Marrow Transplantation; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Radiation Oncology; Fraternal Order of Eagles Diabetes Research Center; Neurosurgery; Holden Comprehensive Cancer Center; Internal Medicine
- Record Identifier
- 9984315657702771
Metrics
17 Record Views